SOTIO to Present Final Phase I/II DCVAC/LuCa Data at ASCO 2019 Annual Meeting

SOTIO logo

PRAGUE, Czech Republic, May 20, 2019 / B3C newswire / -- SOTIO, a biotechnology company owned by the PPF Group, today announces that final data from the SLU01 Clinical Trial with DCVAC/LuCa will be presented in poster session at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago on June 2, 2019. Final analysis of SLU01 data confirmed promising clinical efficacy of DCVAC/LuCa active cellular immunotherapy product in patients with stage IV non-small cell lung cancer.

SOTIO will attend ASCO 2019 (May 31 to June 4, 2019) with its own exhibition booth (#5147) and will present its clinical development pipeline to expert community.

Details for the ASCO presentation are as follows:

Poster presentation at “Lung Cancer—Non-Small Cell Metastatic” Session

Title: Dendritic-cell vaccine (DCVAC) with first-line chemotherapy in patients with stage IV NSCLC: Final analysis of phase II, open label, randomized, multicenter trial.

Session: Lung Cancer—Non-Small Cell Metastatic
Date and time: Sunday, June 2, 8:00 a.m. to 11:00 a.m.
Location: Hall A, Poster Board #362
Presenter: Libor Havel, MD, Thomayer University Hospital (Prague, Czech Republic), principal investigator of SLU01 clinical trial

The abstract with final SLU01 clinical trial data with the DCVAC/LuCa medicinal product targeting patients with non-small cell lung cancer is available online here: Abstract 9039.


About SLU01 clinical trial
SLU01 is a randomized, open-label, three-arm, parallel group, multi-center Phase I/II clinical trial evaluating the safety and efficacy of DCVAC/LuCa added to standard first-line chemotherapy with carboplatin and paclitaxel +/- immune enhancers in patients with stage IV non-small cell lung carcinoma (NSCLC).

The SOTIO DCVAC product candidates are active cellular immunotherapy treatments which are produced individually for each patient using the patient’s own dendritic cells (which form part of the immune system) to induce an immune reaction against tumor antigens.  SOTIO is developing three product candidates using the DCVAC platform to affect multiple different cancers in various stages of the disease - DCVAC/LuCa for patients with lung cancer, DCVAC/OvCa for patients with ovarian cancer and DCVAC/PCa for patients with prostate cancer.

The company is currently testing the safety and efficacy of investigational medicinal treatment DCVAC through multiple Phase I to Phase III clinical trials.

SOTIO is an international biotechnology company leading the efforts of PPF Group to build a diverse biotechnology portfolio through its own research & development, collaborations, in-licensing, investments, mergers and acquisitions. The company is developing new medical therapies, focusing on the treatment of cancer and autoimmune diseases. The most advanced project is the SOTIO proprietary platform of active cellular immunotherapy (ACI) based on dendritic cells. SOTIO is conducting multiple Phase I to Phase III clinical trials verifying the safety and efficacy of its DCVAC products. SOTIO is also collaborating with NBE-Therapeutics on the development of novel antibody-drug conjugate products (ADC), with Cytune Pharma on developing novel IL15-based immunotherapies for the treatment of cancer and with LDC and the Max Planck Society on an oncology program addressing a novel target in tumor metabolism. SOTIO has facilities in Europe, the United States, China and Russia.

SOTIO is a registered trademark of SOTIO a.s. in selected countries.



Richard Kapsa
Head of Communication
T: (+420) 224 174 448
M: (+420) 603 280 971
This email address is being protected from spambots. You need JavaScript enabled to view it.


Published by B3C newswire and shared through Newronic®

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.